Blood Extraction Platform

Description

This contract is for 6 years with an options 1 year extension. Full details are provided in the Invitation To Tender pack. This is provided in the SAP Ariba portal. In 2018 NHSE commissioned Genomic Laboratory Hubs (GLHs) for the delivery of high-quality, efficient, and centralised genomic services. The South West GLH is hosted at NBT, all core rare disease, cancer testing and specialised rare disease testing in cardiology, renal and neurology is provided from the Bristol Genetics laboratory (BGL). The purpose of this notice is to alert potential suppliers to an opportunity to provide a high throughput DNA extraction platform capable of extracting DNA from venous blood where sample volumes are greater than 2ml and be able to produce a high yield of high molecular weight (>48kb) genomic DNA to BGL. The system must produce minimum DNA yields which average between 40 and 100 micrograms of DNA from 2-10ml of human blood. This is key to ensure that the platform can meet the requirements of our Facioscapulohumeral muscular dystrophy (FSHD) service for which 95% of diagnoses are made through genomic testing using Southern Blotting. The total funding available for this capital equipment procurement is £350,000 (inclusive of VAT) however reagent and consumable costs will also be taken into consideration when assessing the Whole Life Cost of the award. Therefore, the estimated total value is inclusive of this.

Links & Documents

Similar contracts